Welcome to „BIOMED-LUBLIN" S.A.

  • Increase font size
  • Default font size
  • Decrease font size
1 2 3 4 5



(Lactobacillus rhamnosus)


2 bn CFU of Lactobacillus rhamnosus bacilli:
Lactobacillus rhamnosus strain penicillin-resistant - 40 %
Lactobacillus rhamnosus strain erythromycin- and neomycin-resistant - 40 %
Lactobacillus rhamnosus strain oxytetracycline-resistant - 20 %
Bacilli resistant to: amoxicillin, ampicillin, azlocilin, cephradin, cephtazidim, cephuroxim,
doxycycline, erythromycin, gentamycin, imipenem, clindamicin, cloxacilin, colistin, nalidixic acid, neomycin, netilmycin, penicillin, piperacilin, streptomycin, tobramicin, vankomycin.
CFU - colony formation unit.
For excipients see the list of excipients


Powder for the preparation of oral suspension.


Indications for use

post-antibiotic enteritis with particular reference to the auxiliary treatment in pseudomembranous colitis; for the treatment of most types of recurring pseudomembranous colitis, the prevention of diarrhoea in travellers, and auxiliary treatment during and after treatment with antibiotics.

Dosage and method of administration

The product is to be administered orally.
The dosage, if not otherwise recommend by a physician, is one dose, 3 - 4 times daily (contents of an ampoule).


Hypersensitivity to the protein of cow's milk.

Special warnings and precautions for use


Interactions with other medicinal products and other forms of interactions


Pregnancy and lactation

The product can be used in pregnant and breast feeding women.

Effects on ability to drive and use machines

No effect on the ability to drive or use machines after LAKCID administration have been observed.

Undesirable effects

Have not been observed.


The consequences of an overdose have not been observed.


Pharmacodynamic properties

Pharmacotherapeutic group: antidiarrheal microorganisms: ATC code A07FA

Lactobacillus rhamnosus strains present in the medicinal product, as with other bacteria
of lactic acid, colonize the mucous membrane of the intestines and normalize the composition of the microflora of the alimentary tract, especially after its impoverishment resulting from treatment with antibiotics. The results of research have confirmed that such strains survive in the habitat of gastric juice, and are resistant to the activity of bile acids salts, which facilitates their adaptation and survival rate in the alimentary tract. Competing for substrata and a place for colonization in the intestinal mucous membrane, and producing lactic acid as a result of the anaerobic decomposition of sugars, produce unfavourable conditions for the development of most pathogenic microorganisms.

These strains possess a natural resistance to a wide spectrum of antibiotics used clinically.

Pharmacokinetic properties

Does not apply.

Preclinical safety data

In research on laboratory animals (guinea pigs and mice) no toxicity of LAKCID has been observed.


List of excipients

Skim-milk, saccharose.

Pharmaceutical incompatibilities

Does not apply.

Shelf life

12 months

Special precautions for storage

Store at 2°C - 8°C (refrigerated).
Keep away from children.

Nature and contents of package

10 ampoules with powder, 1 dose each
50 ampoules with powder, 1 dose each
Ampoules made of neutral glass, volume of 2 ml, in cardboard boxes.

Instructions for use and handling and disposal of medicinal product

Open the ampoule directly before use by carefully pressing down on the ampoule’s neck. The pressing point on the ampoule is marked with a dot. Add a small amount of water or milk which has been boiled and cooled to room temperature, and mix thoroughly. Touch the side of a spoon with the edge of the open ampoule. The suspension will flow down onto the spoon. Use orally.